Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

被引：76
|
作者：
Nakamura, Atsushi
Inoue, Akira
Morita, Satoshi
Hosomi, Yukio
Kato, Terufumi
Fukuhara, Tatsuro
Gemma, Akihiko
Takahashi, Kazuhisa
Fujita, Yuka
Harada, Toshiyuki
Minato, Koichi
Takamura, Kei
Kobayashi, Kunihiko
Nukiwa, Toshihiro
机构：
[1] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[2] Tohoku Univ, Dept Palliat Med, Sch Med, Sendai, Miyagi, Japan
[3] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan
[4] Komagome Hosp, Dept Thorac Oncol & Resp Med, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[7] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan
[8] Juntendo Univ, Dept Resp Med, Sch Med, Tokyo, Japan
[9] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan
[10] JCHO Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[11] Gunma Prefectural Canc Ctr, Div Resp Med, Ota, Japan
[12] Obihiro Kosei Gen Hosp, Dept Med 1, Obihiro, Hokkaido, Japan
[13] Saitama Med Univ Int Med Ctr, Dept Resp Med, Hidaka, Japan
[14] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9005
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
    Fukuhara, T.
    Inoue, A.
    Morita, S.
    Sugawara, S.
    Hosomi, Y.
    Ikeda, S.
    Gemma, A.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [2] Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
    Seike, M.
    Inoue, A.
    Sugawara, S.
    Morita, S.
    Hosomi, Y.
    Ikeda, S.
    Watanabe, K.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 496 - 496
  • [3] NEJ009 trial: A randomized phase III study of gefitinib (G) on combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation
    Inoue, Akira
    Hosomi, Yukio
    Maemondo, Makoto
    Sugawara, Shunichi
    Kato, Terufumi
    Takahashi, Kazuhlsa
    Fujita, Yuka
    Gamma, Aklhlko
    Harada, Toshiyuki
    Oizumi, Satoshi
    Minato, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.
    Miyauchi, Eisaku
    Morita, Satoshi
    Nakamura, Atsushi
    Hosomi, Yukio
    Watanabe, Kana
    Ikeda, Satoshi
    Seike, Masahiro
    Fujita, Yuka
    Minato, Koichi
    Ko, Ryo
    Harada, Toshiyuki
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef plus C).
    Noronha, Vanita
    Joshi, Amit
    Patil, Vijay Maruti
    Chougule, Anuradha
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Kumar, Rajiv
    More, Sucheta
    Goud, Supriya
    Kadam, Nandkumar
    Daware, Nilesh
    Shah, Srushti
    Yadav, Akanksha
    Dutt, Amit
    Trivedi, Vaishakhi
    Behel, Vichitra
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Gefitinib in combination with pemetrexed in patients with advanced non-small cell lung cancer harboring EGFR mutations: is there any difference in acquired resistance mechanism between gefitinib monotherapy and the combination treatment?
    Yoshida, Tatsuya
    Hida, Toyoaki
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S508 - S511
  • [7] Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR
    Miyauchi, Eisaku
    Morita, Satoshi
    Nakamura, Atsushi
    Hosomi, Yukio
    Watanabe, Kana
    Ikeda, Satoshi
    Seike, Masahiro
    Fujita, Yuka
    Minato, Koichi
    Ko, Ryo
    Harada, Toshiyuki
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3587 - +
  • [8] GEFITINIB (G) AND PEMETREXED (PEM) AS A FIRST LINE TREATMENT IN PATIENTS WITH EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Yoshimura, N.
    Matsuura, K.
    Mitsuoka, S.
    Asai, K.
    Tochino, Y.
    Kimura, T.
    Nakai, M.
    Mitsukawa, Y.
    Hirata, K.
    Kudoh, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 412 - 413
  • [9] Phase II study of carboplatin and pemetrexed followed by gefitinib for patients with advanced non-small cell lung cancer harboring sensitive EGFR mutation.
    Manabe, Saki
    Oshita, Fumihiro
    Murakami, Shuji
    Kondo, Tetsuro
    Saito, Haruhiro
    Kaneko, Takeshi
    Yamada, Kouzo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Saijo, Y.
    Genma, A.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    EJC SUPPLEMENTS, 2009, 7 (03): : 6 - 6
12345